The observation that BRCA1-and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in homologous recombination 1 . The cytotoxicity of PARP inhibitors depends on PARP trapping, the formation of non-covalent protein-DNA adducts composed of inhibited PARP1 bound to DNA lesions of unclear origins 1-4 . To address the nature of such lesions and the cellular consequences of PARP trapping, we undertook three CRISPR (clustered regularly interspersed palindromic repeats) screens to identify genes and pathways that mediate cellular resistance to olaparib, a clinically approved PARP inhibitor 1 . Here we present a high-confidence set of 73 genes, which when mutated cause increased sensitivity to PARP inhibitors. In addition to an expected enrichment for genes related to homologous recombination, we discovered that mutations in all three genes encoding ribonuclease H2 sensitized cells to PARP inhibition. We establish that the underlying cause of the PARP-inhibitor hypersensitivity of cells deficient in ribonuclease H2 is impaired ribonucleotide excision repair 5 . Embedded ribonucleotides, which are abundant in the genome of cells deficient in ribonucleotide excision repair, are substrates for cleavage by topoisomerase 1, resulting in PARP-trapping lesions that impede DNA replication and endanger genome integrity. We conclude that genomic ribonucleotides are a hitherto unappreciated source of PARP-trapping DNA lesions, and that the frequent deletion of RNASEH2B in metastatic prostate cancer and chronic lymphocytic leukaemia could provide an opportunity to exploit these findings therapeutically.
were found at an FDR threshold of less than 10% in at least two cell lines. This analysis identified 64, 61 and 116 genes, the inactivation of which caused sensitization to olaparib in the HeLa, RPE1-hTERT and SUM149PT cell lines, respectively, giving a total of 155 different genes (Supplementary Table 1 ).
Out of this list, 13 genes scored positive in all three cell lines and a further 60 genes were common to two cell lines, which we combine to define a core set of 73 high-confidence PARP inhibitor (PARPi)resistance genes ( Fig. 1b , Supplementary Table 1 ). Gene Ontology analysis of the 73-and 155-gene sets (Fig. 1c , Extended Data Fig. 1c , respectively) shows strong enrichment for biological processes related to homologous recombination, providing unbiased confirmation that the screens identified bona fide regulators of the response to PARP inhibition. Mapping the 73-gene set on the HumanMine proteinprotein interaction data (Fig. 1d ) generated a highly connected network consisting of DNA damage response genes that include many regulators of homologous recombination (such as BRCA1, BARD1, BRCA2 and PALB2), components of the Fanconi anaemia pathway, as well as the kinases ATM and ATR. Outside or at the edge of the network, we noted the presence of genes encoding the MUS81-EME1 nuclease, splicing and general transcription factors (such as SF3B3/5 and CTDP1) and the three genes coding for the ribonuclease (RNase) H2 enzyme complex (RNASEH2A, RNASEH2B and RNASEH2C). RNASEH2A, RNASEH2B and RNASHE2C were hits in all three cell lines, with RNASEH2A and RNASEH2B being the two highest-scoring genes, as determined by the mean DrugZ value from the three cell lines ( Supplementary Table 1 ). A similar analysis of the 155-gene set generated an even denser network, with additional genes lying at the periphery of a homologous recombination and Fanconi anaemia core (Extended Data Fig. 1d ).
Next, we generated RNase H2-null HeLa, RPE1, SUM149PT and HCT116 clonal cell lines using genome editing (denoted as KO; Extended Data Fig. 2a-d ) and confirmed that RNase H2 deficiency caused hypersensitivity to both olaparib and a second clinical-stage PARPi, talazoparib, in all cell lines tested ( Fig. 2a, b , Extended Data Fig. 2e -g, with half-maximal effective concentration (EC 50 ) values reported in Extended Data Fig. 2h ). The RNASEH2A KO and RNASEH2B KO cells also exhibited increased levels of apoptosis after PARP inhibition (Extended Data Fig. 2i -l), a phenotype that was particularly prominent with talazoparib treatment (Extended Data Fig. 2i-l) . Given the strength of the PARPi-induced phenotypes in RNase H2-deficient cells, and as RNase H2 had not previously been linked to the response to PARP inhibition, we sought to determine the mechanism of PARPi sensitization in RNase H2-deficient cells.
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As deficiency in homologous recombination causes PARPi sensitivity, we first considered that RNase H2 might promote homologous recombination. Consistent with this possibility, fission yeast cells that combine mutations in RNase H2 and RNase H1 have defects in homologous recombination 9 . However, in RNase H2-deficient cells, RAD51 readily formed ionizing radiation-induced foci, suggesting efficient recombinase filament assembly ( Fig. 2c, d , Extended Data Fig. 3a, b ). Furthermore, the efficiency of homologous recombination, as assessed by the direct repeat-green fluorescent protein (DR-GFP) assay 10 , was at near wild-type levels in cells transduced with RNASEH2A and RNASEH2B short guide RNAs (sgRNAs) ( Fig. 2e , Extended Data Fig. 3c, d) . Third, rather than presenting reduced homologous recombination, RNASEH2A KO cells displayed higher levels of sister chromatid exchanges, reminiscent of the 'hyper-rec' phenotype observed in RNase H2-deficient yeast 11 (Fig. 2f ). This phenotype was probably caused by increased levels of replication-dependent DNA damage, as determined by γ-H2AX staining (Fig. 2g , Extended Data Fig. 3e -h) and marked poly(ADP-ribosylation) of PARP1 ( Fig. 2h, Extended Data Fig. 3i, j) , supporting previous observations of replication-associated genome instability in yeast and mammalian cells deficient in RNase H2 [12] [13] [14] .
The increased levels of sister chromatid exchanges prompted us to test whether RNase H2-deficient cells required homologous recombination for survival. Indeed, we observed synthetic lethality when an sgRNA against RNASEH2B was delivered into engineered BRCA1 KO and BRCA2 KO cell lines in the RPE1-hTERT and DLD-1 backgrounds, respectively ( Fig. 2i , Extended Data Fig. 3k-o) .
RNase H2 cleaves single ribonucleotides incorporated into DNA, as well as longer RNA-DNA hybrids 15 . To distinguish between these two functions, we carried out cellular complementation experiments with variants of RNase H2. The sensitivity of RNASEH2A KO cells to olaparib was not rescued by either a catalytically-inactive RNase H2 enzyme (RNASEH2A(D34A/D169A)), or by a separation-of-function mutant (RNASEH2A(P40D/Y210A) 16 ) that retains activity against RNA-DNA hybrids, but not DNA-embedded monoribonucleotides (Fig. 2j , Extended Data Fig. 4 ). These data indicate that it is probably the removal of genome-embedded ribonucleotides by ribonucleotide excision repair (RER), and not RNA-DNA hybrid cleavage by RNase H2, that protects cells from PARPi-induced cytotoxicity.
To determine the genetic basis of the sensitivity of RNASEH2A KO cells to PARPi, we carried out CRISPR screens to identify mutations that restored resistance to talazoparib in RNase H2-deficient HeLa and RPE1-hTERT cell lines ( Fig. 3a , Extended Data Fig. 5a , Supplementary  Table 2 ). The screens identified a single common gene, PARP1. The genetic dependency on PARP1 for talazoparib-and olaparib-induced cytotoxicity was confirmed in double mutant RNASEH2A KO PARP1 KO cells (Fig. 3b , Extended Data Fig. 5b-e ), providing evidence that the lethality associated with PARP inhibition requires formation of trapped PARP1-DNA adducts 4 . Consistent with this finding, treatment with veliparib, a PARP inhibitor with poor trapping ability 4 induced much less apoptosis than olaparib or talazoparib in RNASEH2A KO cells (Extended Data Fig. 5f ).
Analysis of DNA content by flow cytometry revealed that RNASEH2A KO cells arrest in S phase in a PARP1-dependent manner upon talazoparib treatment (Fig. 3c, Extended Data Fig. 5g ). RNASEH2A KO cells also demonstrated increased levels of talazoparibinduced γ-H2AX and these levels did not decline upon drug removal ( Fig. 3c, Extended Data Fig. 5h ). These observations suggest that unresolved DNA lesions induced by PARP trapping are the likely cause of cell death in PARPi-treated RNASEH2A KO cells.
Genome instability in RER-deficient yeast cells is dependent on an alternative, topoisomerase 1 (TOP1)-mediated ribonucleotide excision pathway [17] [18] [19] . In this process, TOP1 enzymatic cleavage 3′ of the embedded ribonucleotide results in DNA lesions predicted to engage PARP1, including nicks with difficult-to-ligate 2′-3′-cyclic phosphate ends 17, 18, 20 and covalent TOP1-DNA adducts (TOP1 cleavage complexes 21 ) in conjunction with single-strand DNA gaps or double-strand breaks 22 . Given that the mechanisms promoting genome instability in mammalian RNase H2-deficient cells remain poorly defined, we assessed whether TOP1 action on misincorporated ribonucleotides contributed to the DNA damage observed in human RER-deficient cells. Short-term depletion of TOP1 using short interfering RNAs (siRNAs) reduced the number of γ-H2AX foci in RNase H2-deficient cells to nearly wild-type levels ( Fig. 3d -f, Extended Data Fig. 6a ). Furthermore, TOP1-mediated ribonucleotide cleavage contributed to PARPi sensitivity, as depletion of TOP1 with independent siRNAs in RNASEH2A KO cells reduced the levels of talazoparib-induced apoptosis ( Fig. 3g , Extended Data Fig. 6b-e ). TOP1 depletion also reduced talazoparib-induced apoptosis in the RER-deficient RNASEH2A(P40D/ Y210A) cells (Extended Data Fig. 6f -h) and ameliorated the talazoparibinduced S-phase arrest (Extended Data Fig. 6i ). Together, these results strongly suggest that the processing of genome-embedded ribonucleotides by TOP1 leads to DNA lesions that engage PARP1, creating a vulnerability to PARP trapping.
The RNASEH2B gene resides on chromosome 13q14 in proximity to two tumour suppressor loci. One of them, the DLEU2-mir- [15] [16] microRNA cluster, is a target of 13q14 deletions observed in over 50% of chronic lymphocytic leukaemia (CLL) cases 23 . As a result, collateral homozygous deletion of RNASEH2B can occur in CLL and other haematopoietic malignancies 24 . Additionally, in prostate cancer, frequent deletions at 13q14 involving the RB1 but not the BRCA2 locus 25 might also result in RNASEH2B loss. Such 13q14 deletions are late events associated with endocrine-therapy resistance, luminal-to-basal phenotype transition and rapid disease progression 26, 27 . 
We determined RNASEH2B copy number by multiplex ligationdependent probe amplification (MLPA) in 100 patients with CLL. RNASEH2B deletions were present in 43% of CLL samples, with biallelic loss detected in 14%. Co-deletion of the DLEU2 microRNA cluster was confirmed by comparative genomic hybridization (CGH) microarray ( Fig. 4a , Extended Data Fig. 7a, b ), establishing that collateral RNASEH2B loss is frequent in CLL. Furthermore, analysis of whole-exome sequencing of metastatic castration-resistant prostate cancers (CRPCs) 28 demonstrated frequent collateral loss of RNASEH2B with RB1 gene deletion co-occurring in 34% of tumours (2% biallelic loss; Extended Data Fig. 7c ).
The frequent collateral deletion of RNASEH2B prompted us to test whether RNASEH2B loss in cancer cells could be an actionable vulnerability to PARP inhibition. To do so, we performed ex vivo analysis on primary CLL cells derived from 21 of the 100 patient samples assayed above. Patient characteristics of selected samples were similar across groups (Extended Data Table 1 ). RNase H2 status was confirmed by enzymatic assay of CLL lysates ( Fig. 4b ) and short-term CLL cultures were established from peripheral blood leukocyte samples by stimulating their proliferation with IL21 and co-culture with CD40-ligand expressing MEFs (Extended Data Fig. 8a , b, Supplementary Fig. 2 ). RNASEH2B-deficient cells were found to be significantly more sensitive to PARPi and especially to talazoparib, with the degree of sensitivity correlating with number of RNASEH2B alleles lost ( Fig. 4c , Extended Data Fig. 8c ).
We then asked whether RNase H2 deficiency also confers PARPi sensitivity to tumours in xenograft experiments, using isogenic HCT116 cells with and without RNASEH2A deletion (Extended Data Fig. 2a , g, l). Cells were implanted in the flanks of CD-1 nude mice and, following establishment of tumours, mice were treated with talazoparib given its higher trapping activity. While talazoparib treatment did not lead to tumour regression, we observed significantly higher sensitivity to talazoparib in tumours lacking RNase H2 ( Fig. 4d ). Furthermore, a second xenograft experiment confirmed this sensitivity to be specific Table 1 , Supplementary Table 3 .
to RNase H2 loss as complementation with an RNASEH2A transgene abrogated PARPi sensitivity (Extended Data Fig. 8d ). We conclude that collateral loss of RNase H2 enhances the vulnerability of cancer cells to PARP-trapping drugs.
Finally, we note that genome-embedded ribonucleotides are by far the most abundant aberrant nucleotides in the genome of cycling cells 13 and may thus represent a major source of the traps that mediate the cytotoxicity of PARPi alongside base excision repair intermediates. In support of this possibility, RNASEH2A KO cells are more sensitive to PARPi than isogenic cell lines with homozygous mutations in the catalytic domain of DNA polymerase-β (POLB Δ188-190 ), a key enzyme in base excision repair (Extended Data Fig. 9 ). We therefore propose a model whereby the canonical RER pathway and TOP1 compete for the processing of genome-embedded ribonucleotides (Fig. 4e ). Whereas RNase H2 cleavage initiates their problem-free removal, the action of TOP1 on ribonucleotides creates PARP-trapping DNA lesions that impair successful completion of DNA replication and the resulting burden of genomic lesions ultimately causes cell death. We propose that the manipulation of genomic ribonucleotide processing could be harnessed for therapeutic purposes and this strategy may expand the use of PARP inhibitors to some tumours that are proficient in homologous recombination. 29 , a gift from B. Vogelstein, were maintained in modified McCoy's 5A medium (Gibco/ Thermo Fisher) supplemented with 10% FBS and Pen/Strep. SUM149PT cells were purchased from Asterand BioScience and grown in a DMEM/F12 medium mixture (Gibco/Thermo Fisher) supplemented with 5% FBS, Pen/Strep, 1 μg ml −1 hydrocortisone and 5 μg ml −1 insulin (both Sigma). Wild-type and BRCA2 KO DLD-1 cells were purchased from Horizon and maintained in RPMI medium (Gibco/ Thermo Fisher) supplemented with 10% FBS and Pen/Strep. All cell lines were grown at 37 °C and 5% CO 2. HeLa, RPE1-hTERT (with the exception of BRCA1 KO and POLB Δ188-190 clones) and HCT116 cells were grown at atmospheric O 2 . RPE1-hTERT BRCA1 KO and POLB Δ188-190 clones, as well as DLD-1 and SUM149PT cell lines were maintained at 3% O 2 . Lentiviral and retroviral transduction. To produce lentivirus, 4.5 × 10 6 293T cells in a 10-cm dish were transfected with packaging plasmids (5 μg pVSVg, 3 μg pMDLg/pRRE and 2.5 μg pRSV-Rev) along with 10 μg of transfer plasmid using calcium phosphate. Medium was refreshed 12-16 h later. Virus-containing supernatant was collected ~36-40 h post transfection, cleared through a 0.4-μm filter, supplemented with 4 μg ml −1 polybrene (Sigma) and used for infection of target cells. The TKOv1 library virus was prepared as previously described 30 . The following antibiotics were used for selection of transductants: puromycin (HeLa, SUM149PT: 2 μg ml −1 ; RPE1-hTERT 15-20 μg ml −1 ; each for 48-72 h unless indicated otherwise) and blasticidin (5 μg ml −1 , 4-5 days for all cell lines). Cells stably expressing Flag-Cas9-2A-Blast were maintained in the presence of 2 μg ml −1 blasticidin.
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To complement the HCT116 TP53 KO RNASEH2A KO cell line, cells were infected with retroviral supernatant produced in amphotropic Phoenix packaging cells 31 using either pMSCVpuro empty vector (EV) or pMSCVpuro-RNASEH2A-WT in the presence of 4 μg ml −1 polybrene (Sigma) and 48 h later selected for stable integration using 2 μg ml −1 puromycin. RNASEH2A expression plasmids. A Flag-tagged human RNASEH2A cDNA (NM_006397.2; encoding amino acids 2-299) and the D34A/D169A double mutant 32 were cloned into the pCW57.1 vector (a gift from D. Root; Addgene #41393) using the Gateway system (Life Technologies/Thermo Fisher) according to the manufacturer's protocol. The P40D and Y210A mutations were generated by site-directed mutagenesis using the following primers (5′ to 3′): P40D forward, GGCCCAGCACGTCGCCCCTGCCCG; P40D reverse, CGGGCAGG GGCGACGTGCTGGGCC; Y210A forward, GTCTTGGGATCATTGGGG GCGCCTGAGCCATAATCAGT; Y210A reverse, ACTGATTATGGCTCAGG CGCCCCCAATGATCCCAAGA. Expression constructs were introduced into HeLa RNASEH2A KO cells by lentiviral transduction and expression was induced by the addition of 1 μg ml −1 doxycycline (Clontech) 24 h before starting experiments. The pMSCVpuro-RNASEH2A-WT plasmid was generated by cloning the coding sequence of human RNASEH2A into pMSCVpuro-Dest, a Gatewaycompatible version of pMSCVpuro (Clontech), and introduced into HCT116 TP53 KO RNASEH2A KO cells by retroviral transduction. sgRNA target sequences. sgRNAs targeting the following sequences (5′ to 3′) were used to generate CRISPR knockouts. RNASEH2A, TGCCCGCCTCATCGA CGCCC and CCCGTGCTGGGTGCGCCCCT (for Hela RNASEH2A KO ); GACCCTATTGGAGAGCGAGC (for HeLa Cas9, RPE1-hTERT, HeLa DR-GFP); RNASEH2B, TCCACCACAACTTGATCAAG; PARP1, TAACGATGTCCA CCAGGCCA; BRCA1, AAGGGTAGCTGTTAGAAGGC; POLB, GAGAACATCC ATGTCACCAC; LacZ, CCCGAATCTCTATCGTGCGG; PSMD1-1, TGTGCGCTA CGGAGCTGCAA; PSMD1-2, ACCAGAGCCACAATAAGCCA; PSMB2-1, ATGTTCTTGTCGCCTCCGAC; PSMB2-2, AATATTGTCCAGATGAAG GA; EIF3D-1, TGTAGGTTGCCTCCATGGCC; EIF3D-2, AGACGACCCTGTCA TCCGCA; TP53, CAGAATGCAAGAAGCCCAGA.
Vectors expressing the Cas9n D10A nickase together with guide RNAs designed against exon 1 and intron 1 of human RNASEH2A were generated by cloning annealed DNA oligonucleotides into pSpCas9n(BB)-2A-GFP and pSpCas9n(BB)-2A-Puro vectors (Addgene plasmid #48140 and #48141, respectively; gifts from F. Zhang) as previously described 33 . All other sgRNA-expressing constructs were generated by cloning annealed DNA oligonucleotides into lentiGuide-Puro or lentiCRISPR v2 vectors (Addgene #52963 and 52961, gifts from F. Zhang) as previously described 34 . RNA interference. TOP1 was targeted with 40 nM of either a custom siRNA (siTOP1, target site sequence AAGGACTCCATCAGATACTAT, Sigma) previously described 35 or an ON-TARGETplus SMARTpool siRNA (siTOP1-SP, L-005278-00, Dharmacon/BD Technologies), that has previously been used to knock down TOP1 [36] [37] [38] . A custom siRNA targeting luciferase (siCTRL, CTTACGCTGAGTACTTCGA, Sigma) or an ON-TARGETplus non-targeting pool (siCTRL-SP, D-001810-10-05, Dharmacon/BD Technologies) were used as controls 39 . siRNA oligonucleotides were transfected in Opti-MEM reduced-serum medium using oligofectamine (Life Technologies/Thermo Fisher). To improve knockdown efficiency for the ON-TARGETplus siRNA, a second round of transfection was conducted after 24 h. Following siRNA transfection, cells were seeded either for cell cycle analysis (24 h post last transfection) or for immunofluorescence analysis (48 h post transfection) as described below. Knockdown was optimised to minimize cell death, while maintaining efficient TOP1 depletion (apoptosis levels ≤ 14% of control transfected cells). DNA damaging drugs. PARP inhibitors olaparib, talazoparib and veliparib were purchased from Selleck Chemicals. Talazoparib for the xenograft experiments was a gift of T. Heffernan and N. Feng. Methyl methanesulfonate (MMS) and aphidicolin were obtained from Sigma. Concentrations and durations of treatment are indicated in the sections below and in the respective figures. Generation of Cas9-expressing cells. Cells were transduced with the Lenti-FLAG-Cas9-2A-Blast vector 30 and transductants were selected with blasticidin. Cells were then seeded at low densities (500-1,000 cells, depending on the cell line) on 15-cm dishes and single colonies were isolated using glass cylinders. Cas9 expression was confirmed by immunoblotting and gene editing efficiency was tested as follows.
Cells were transduced at a low (~0.3) multiplicity of infection (MOI) with either a control LacZ sgRNA construct or sgRNA constructs targeting essential genes PSMD1, PSMB2 and EIF3D 30 and then selected with puromycin. Cells (2.5 × 10 4 ) were subsequently seeded in 6-well plates, medium was exchanged 3 days later and the experiment was terminated at day six. Cells were trypsinized, resuspended in medium and the live cell count was determined by trypan blue exclusion on a ViCELL instrument (Beckman Coulter). Cell numbers were plotted relative to sgLacZ-transduced samples.
Generation of CRISPR knockout cell lines. To establish HeLa and HCT116
TP53 KO RNASEH2A KO cell lines, 0.5 × 10 6 cells were seeded in 6-well plates and transfected with two vectors encoding both Cas9n and sgRNAs targeting RNASEH2A (derivatives of pSpCas9n(BB)-2A-GFP and pSpCas9n(BB)-2A-Puro) using Lipofectamine 2000 (Life Technologies/Thermo Fisher). Forty-eight hours after transfection, single GFP + cells were sorted into 96-well plates on a BD FACSJazz instrument (BD Biosciences) and grown until colonies formed. RNASEH2A KO clones were selected on the basis of the size of PCR amplicons from the targeted region to detect clones that underwent editing, which was subsequently confirmed by Sanger sequencing. The oligonucleotides (5′ to 3′) used for PCR amplification and sequencing of targeted RNASEH2A loci were ACCCGCTCCTGCAGTATTAG and TCCCTTGGTGCAGTGCAATC. The absence of functional RNASEH2A was confirmed by immunoblotting, an RNase H2 activity assay and alkaline gel electrophoresis as described below. Functionally wild-type RNASEH2A clones were identified in parallel and used as controls.
To generate the remaining CRISPR-edited HeLa and RPE1-hTERT cell lines, cells were electroporated with 5 μg of vectors encoding the sgRNA (lentiGuide-Puro, for cells stably expressing Cas9) or encoding both the sgRNA and Cas9 (lentiCRISPR v2) using an Amaxa Nucleofector II instrument (Lonza). RPE1-hTERT cells (0.7 × 10 6 ) in a buffer containing 100 mM Na 2 HPO 4 (pH 7.75), 10 mM KCl and 11 mM MgCl 2 were electroporated using program T-23. For HeLa cells, the Amaxa Cell Line Nucleofector Kit R (Lonza) was used with program I-13 according to the manufacturer's instructions. Cells were re-plated into antibioticfree McCoy's 5A medium supplemented with 10% FBS and allowed to recover for 24 h. Puromycin was subsequently added to growth medium to enrich for transfectants and removed 24 h later. Cells were then cultured for an additional 3-5 days to provide time for gene editing and eventually seeded at low densities (400-1,000 cells, depending on cell line) on 15-cm dishes. Single colonies were isolated using glass cylinders two to three weeks later. SUM149PT Cas9 RNASEH2B KO cells were generated by transient transfection of parental SUM149PT Cas9 cells with a lentiGuide-puro-sgRNASEH2B construct using Lipofectamine 2000 (Thermo Fisher) as per the manufacturers protocol (2 μg plasmid DNA and 2 μl of Lipofectamine 2000 was used for 1 × 10 5 cells in a 6-well plate). Transfected cells were selected with puromycin for 24 h, grown for an additional 4 days and single clones were isolated as above.
Targeted clones were identified by immunofluorescence and/or immunoblotting and successful gene editing was confirmed by PCR and TIDE analysis (https:// tide-calculator.nki.nl) 40 . The following PCR primers (5′ to 3′) were used for amplification of targeted loci in RNASEH2A forward, AGATCTGGAGGCGCTGAAA GT GG, RNASEH2A reverse, AGTGGCTGTATCATGTGACAGGG; RNASEH2B forward, TAGATGGTGTGCTGTGTGG, RNASEH2B reverse, TGCTCAGCT TGTCATTGACC; BRCA1 forward, TCTCAAAGTATTT CATTTTCTTGG TGCC, BRCA1 reverse, TGAGCAAGGATCATAAAATGTTGG; PARP1 forward, AAGCAAACAGGACTGCCAGC, PARP1 reverse, TACGCCACTGCACTC CAGC; POLB forward, TTACTGTTGTCATCA CAGATTCTGC, POLB Letter reSeArCH reverse, AGCAACTCATGGAAGAATAATAGG; TP53 for ward, GCATTGAAGTCTCATGGAAGC; TP53 reverse, TCACT GCCATGGA GGAGC. Generation of wild-type and RNASEH2A KO HeLa FUCCI cells. To establish wild-type RNASEH2A KO HeLa cells expressing the FUCCI cell cycle reporters mKO2-Cdt1 and mAG-Geminin 41 , wild-type and RNASEH2A KO HeLa cells were transduced at a low MOI with pLenti6-mKO2-Cdt1 and pLenti6-mAG-Geminin vectors and transductants were selected with 2 μg ml −1 blasticidin. Subsequently, cells positive for both mKO2-Cdt1 and mAG-Geminin fluorescence were collected by sorting on a BD Biosciences FACS Aria II instrument, expanded and used for further experiments. Expression of mKO2-Cdt1 and mAG-Geminin was confirmed by immunofluorescence and FACS analysis. CRISPR-Cas9 screening. CRISPR screens were performed as described 30 . Cas9expressing cells were transduced with the lentiviral TKOv1 library at a low MOI (~0.2-0.3) and puromycin-containing medium was added the next day to select for transductants. Selection was continued until 72 h post transduction, which was considered the initial time point (day 0). At this point the transduced cells were split into technical triplicates. During negative-selection screens (for PARPi sensitizers), cells were subcultured at day 3 and at day 6 each of the three replicates was divided into two populations. One was left untreated and to the other a dose of olaparib amounting to 20% of the lethal dose (LD 20 ) (HeLa, 2 μM; RPE1-hTERT, 0.5 μM; SUM149PT, 0.2 μM) was added. Cells were grown with or without olaparib until day 15 and subcultured every three days. Sample cell pellets were frozen at each time point for genomic DNA (gDNA) isolation. A library coverage of ≥200 cells per sgRNA was maintained at every step. Positive-selection screens (for suppressors of sensitivity) were carried out in a similar way, but the untreated control was left out, an LD 80 dose of talazoparib was used (20 and 50 nM for HeLa and RPE1-hTERT, respectively), cells were subcultured only once after drug addition (day 12-13) and screens were terminated at day 18. Library coverage was ≥100 cells per sgRNA.
gDNA from cell pellets was isolated using the QIAamp Blood Maxi Kit (Qiagen) and genome-integrated sgRNA sequences were amplified by PCR using the KAPA HiFi HotStart ReadyMix (Kapa Biosystems). i5 and i7 multiplexing barcodes were added in a second round of PCR and final gel-purified products were sequenced on Illumina HiSeq2500 or NextSeq500 systems to determine sgRNA representation in each sample. DrugZ 8 was used to identify gene knockouts, which were depleted from olaparib-treated day-15 populations but not depleted from untreated cells. Gene knockouts enriched at day 18 as compared to day 6 in positive-selection screens were identified using MAGeCK 42 . Gene Ontology and interaction network analyses. PANTHER (http://pantherdb. org) 43 was used to identify Gene Ontology (GO) biological processes enriched in datasets of screen hits as compared to genome-wide representation. Hits (FDR ≤ 0.01 in at least one cell line and FDR ≤ 0.1 in at least two cell lines) from individual cell lines or hits common to at least two cell lines were analysed with the 'statistical overrepresentation test' (Gene Ontology ontology database released 28 February 2017; annotation dataset 'GO biological process complete') with Bonferonni correction for multiple testing. Mapping of the hits on the HumanMine protein interaction network was done using the esyN interface (http://www.esyn. org/). The network was then exported and visualized in Cytoscape v.3.4.0 (http:// www.cytoscape.org/) and the node sizes adjusted to be proportional to the averaged DrugZ score over the three cell lines. Clonogenic survival assays. To determine PARPi sensitivity cells were seeded on 10-cm dishes (500-3,000 cells per plate, depending on cell line and genotype) into drug-free medium or media containing a range of PARPi concentrations. Cells were either treated for 2 days with talazoparib followed by additional 9-12 days of growth in drug-free media (HeLa, SUM149PT), treated for 7 days with talazoparib followed by 5-6 days in drug-free media (RPE1-hTERT, HCT116), or treated continuously for 12-13 days with olaparib. The cultures were incubated at 3% O 2, with the exception of the experiment in Fig. 2j , which was carried out at atmospheric O 2 . Medium (with or without PARPi) was refreshed every 4-7 days in all cases. At the end of the experiment medium was removed, cells were rinsed with PBS and stained with 0.4% (w/v) crystal violet in 20% (v/v) methanol for 30 min. The stain was aspirated and plates were rinsed 2× in ddH 2 O and air-dried. Colonies were manually counted and data were plotted as surviving fractions relative to untreated cells. To calculate EC 50 values the data were fit to a three-parameter dose response model (log(inhibitor) versus normalized response) using the nonlinear regression function in Graphpad PRISM v6.0.
To analyse the synthetic lethality of combined BRCA1 and RNASEH2B knockouts, wild-type BRCA1 and BRCA1 KO RPE1-hTERT Cas9 TP53 KO cells were transduced at a high MOI (>1.0) with lentiGuide sgRNA constructs targeting either RNASEH2B or LacZ (control) and seeded for clonal growth 48 h later. Wild-type and BRCA1 KO colonies were grown at 3% O 2 for 12 and 20 days (owing to the slower growth of BRCA1-deficient cells), respectively. Synthetic lethality between RNase H2 and BRCA2 was assessed by transducing wild-type and BRCA2 KO DLD-1 cells with either an empty lentiCRISPR v2 vector or lentiCRISPR v2 constructs carrying sgRNASEH2A or sgRNASEH2B. Cells were selected with puromycin and seeded for clonogenic assays 7 days post infection. Clones were grown at 3% O2 for 11 (wild type) or 14 days (BRCA2 KO ). Immunofluorescence microscopy. To analyse γ-H2AX focus formation, cells were grown on coverslips for 24 h, incubated in medium containing 10 μM EdU for 20 min to label cells undergoing DNA replication, then pre-extracted for 5 min on ice with ice-cold buffer (25 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl 2 , 300 mM sucrose and 0.5% Triton X-100) and fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature (RT). After fixation, cells were washed with PBS and blocked in 3% FBS in PBS for 30 min at room temperature. EdU immunolabelling was performed using the Click-iT EdU Imaging Kit (Invitrogen, C10337). Afterwards cells were incubated with a primary mouse antibody against γ-H2AX (Millipore 05-636; 1:800) for 1.5 h at room temperature and then stained with anti-mouse secondary antibodies conjugated to Alexa Fluor-568 (Life Technologies) for 1 h at room temperature. Coverslips were mounted using Vectashield antifade mounting medium with 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). For quantification of γ-H2AX foci images were visualized on a Zeiss Axioplan 2 microscope with a 40× Plan-neofluar objective, captured using Micro-Manager (https://open-imaging.com/) and analysed using an ImageJ-based script as previously described 44 . Nuclei were defined on the basis of DAPI staining, and γ-H2AX foci were detected using the 'Find maxima' function of ImageJ within each nuclear region. Exposure time, binning, microscope settings, light source intensity and the noise level in the 'Find maxima' function were kept constant for all the samples within each individual experiment. More than 100 cells were analysed per condition in each experiment.
For combined γ-H2AX and RAD51 immunofluorescence, 0.25 × 10 6 cells were seeded on coverslips and ~24 h later were subjected to 3 Gy of X-ray irradiation. Two-, four-or six-hour post irradiation cells were incubated with nuclear extraction buffer (20 mM HEPES pH 7.4, 20 mM NaCl, 5 mM MgCl 2 , 0.5% NP-40, 1 mM DTT and protease inhibitors) for 10 min on ice, rinsed with ice-cold PBS and subsequently fixed with 4% PFA for 10 min at room temperature. Cells were blocked in immunofluorescence blocking buffer (10% goat serum, 0.5% NP-40, 0.5% saponin in PBS) for 30 min and incubated with primary antibodies diluted in blocking buffer (Santa-Cruz Biotechnologies rabbit anti-RAD51 and Millipore mouse anti-γ-H2AX; 1:150 and 1:2,000, respectively) for 2 h at room temperature. Cells were then washed with PBS (3× 5 min) and stained with fluorescent secondary antibodies (Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 555-conjugated goat anti-mouse IgG, Life Technologies/Thermo Fisher; 1:1,000 in blocking buffer) and 0.5 μg ml −1 DAPI for 1 h at room temperature. Cells were washed as above, mounted in ProLong Gold mounting medium (Life Technologies/Thermo Fisher) and imaged used a Zeiss LSM780 laser-scanning microscope. Cells with more than five colocalizing γ-H2AX and RAD51 foci were quantified by manual counting. At least 100 cells per condition were analysed in each experiment. Immunofluorescence and flow cytometry. For detection of apoptotic cells by cleaved caspase-3 immunofluorescence FACS, 0.5 × 10 6 cells were plated on 6-cm dishes and either left untreated or treated with PARPi for 48 to 72 h (PARPi doses are indicated in respective figures). For analysis of apoptotic cells following TOP1 depletion, 0.25 × 10 6 cells were plated on 6-cm dishes, transfected with siCTRL or siTOP1 the next day and 24 h post-transfection were either left untreated or treated with PARPi for 48 h. Medium was removed and stored in a conical tube, cells were collected by trypsinization, resuspended in the original conditioned medium and centrifuged at 524g for 5 min at 4 °C. Pellets were washed in PBS and fixed in 1 ml 4% PFA for 10 min at room temperature. Cells were pelleted as above, resuspended in 100 μl PBS and chilled on ice. 900 μl of −20 °C methanol was then added dropwise while gently vortexing. Fixed cells were stored at −20 °C overnight or longer.
Before staining, cells were spun down as above, washed in PBS and blocked in immunofluorescence blocking buffer (see the 'Immunofluorescence' section). Cells were then centrifuged and resuspended in 200 μl of diluted rabbit anti-cleaved caspase-3 antibody (Cell Signaling #9661; 1:800 in immunofluorescence blocking buffer). After 2 h incubation the antibody was diluted with 2 ml PBS, cells were spun down, and incubated for 1 h in 200 μl Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (Molecular Probes/Thermo Fisher, 1:1,000 in IF blocking buffer). The antibody was diluted with 2 ml PBS, cells were centrifuged, resuspended in 1 ml PBS and cleaved caspase-3 signal was analysed on BD FACSCalibur or BD LSRFortessa X-20 instruments. Data were analysed using FlowJo software (Tree Star). See Supplementary Fig. 2 for examples of gating strategies.
For analysis of recovery from talazoparib-induced replication blockage, cells were treated with 1 μM talazoparib for 24 h, washed extensively with PBS and grown in drug-free medium for additional 10, 24 or 34 h. Cells were then collected, fixed, stained as described above using an anti-γH2AX primary antibody (JBW301, Millipore #05-636, 1:1,000 in blocking buffer) and finally DNA was labelled with propidium iodide (see below).
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Cell cycle analysis by FACS. Cells (0.5 ×10 6 ) were seeded on 6-cm dishes into medium with or without PARPi (doses and durations are indicated in respective figures). Cells were then collected by trypsinization, resuspended in medium and centrifuged (233g, 5 min, 4 °C). Pellets were resuspended in PBS, centrifuged again and resuspended in 1 ml propidium iodide staining buffer (20 μg ml −1 propidium iodide, 0.02% Triton X-100, 0.2 mg ml −1 RNase A in PBS). Cells were stained for 15 min at 37 °C and analysed on a BD FACSCalibur or BD LSR Fortessa X-20 instruments.
For combined propidium iodide and EdU staining, cells were treated and collected as above and fixed in 70% ethanol (added dropwise while gently vortexing) overnight at −20 °C. Cells were then centrifuged as above, washed in PBS and incubated with 10 μM Alexa Fluor 488 azide (Molecular Probes/Thermo Fisher) in a buffer containing 100 mM Tris-HCl pH 8.5, 1 mM CuSO 4 and 100 mM ascorbic acid for 30 min before centrifugation, washing in PBS and propidium iodide staining. See Supplementary Fig. 2 for examples of gating strategies. Sister chromatid exchange assay. HeLa cells (0.5 × 10 6 ) were seeded in 10-cm dishes and bromodeoxyuridine (BrdU) (final concentration 10 μM) was added the next day. BrdU containing-medium was refreshed 24 h later and cells were grown for another 22 h (46 h BrdU incubation in total). 100 ng ml −1 KaryoMAX colcemid (Gibco/Thermo Fisher) was added for the final 2 h and cells were collected as follows.
Growth medium was removed and stored in a conical tube. Cells were gently washed with 1 ml of trypsin (the trypsin wash was combined with the original medium), trypsinized, resuspended in the original conditioned medium (with a trypsin wash) and centrifuged (233g, 5 min, 4 °C). Cells were then washed with PBS, spun down, resuspended in pre-warmed 75 mM KCl and incubated for 30 min at 37 °C. Cells were centrifuged again, the supernatant was removed and cells were fixed by drop-wise addition of 1 ml fixative (ice-cold methanol: acetic acid, 3:1) while gently vortexing. An additional 10 ml of fixative was then added and cells were fixed at 4 °C for at least 16 h. Once fixed, metaphases were dropped on glass slides, rinsed with fixative and air-dried overnight (protected from light).
To visualize sister chromatid exchanges (SCE) slides were rehydrated in PBS for 5 min and stained with 2 μg ml −1 Hoechst 33342 (Molecular Probes/Thermo Fisher) in 2× SSC (final 300 mM NaCl, 30 mM sodium citrate, pH 7.0) for 15 min. Stained slides were placed in a plastic tray, covered with a thin layer of 2× SSC and irradiated with 254 nM UV light (~5400 J m −2 ). Slides were subsequently dehydrated in a 70%, 95% and 100% ethanol series (5 min each), air-dried and mounted in DAPI-containing ProLong Gold mounting medium (Molecular Probes/Thermo Fisher). Images were captured on a Zeiss LSM780 laser-scanning microscope. DR-GFP assay and quantitative image-based cytometry. HeLa DR-GFP cells (a gift from R. Greenberg) were transduced with either a lentiCRISPR v2 empty vector or sgRNA-expressing constructs targeting RNASEH2A or RNASEH2B. Seven days after transductions 4-5 × 10 3 cells were plated per well of 96-well imaging plates (Corning 3603) and next day either mock transfected or transfected with either 100 ng of a plasmid expressing I-SceI or a GFP-expressing plasmid (to assess transfection-efficiency) using Lipofectamine 2000. Medium was exchanged 6-8 h later and at 48 h post-transfection cells were fixed in 4% paraformaldehyde. Immunofluorescence for RNASEH2A was performed as described above and plates were imaged on an InCell Analyzer 6000 automated microscope (GE Life Sciences) with a 20× objective. Image analysis was performed using Columbus (PerkinElmer). Nuclei were segmented and a sum of DAPI intensity, mean RNASEH2A intensity and mean GFP intensity was quantified for each nucleus. Cells showing a DNA content between 1N and 2N were selected based on DAPI intensity, RNASEH2A + and RNASEH2A − populations were separated and percentages of GFP + cells were calculated. Only RNASEH2A + cells were analysed in vector-infected samples, whereas only RNASEH2A − cells were considered in sgRNA-transduced samples. Percentages of GFP + cells in each sample were normalized to the transfection efficiency of a control GFP plasmid. Immunoblotting. Cell pellets were resuspended in hot 2× sample buffer (166.7 mM Tris-HCl pH 6.8, 2% SDS, 20 mM DTT, 10% glycerol, 0.01% bromophenol blue) at a concentration of 5 × 10 6 cells ml −1 and denatured at 95 °C for 5 min. An equivalent of 0.25-1 × 10 5 cells was separated by SDS-PAGE and transferred to a nitrocellulose or PVDF (for RNASEH2B) membrane. Membranes were blocked with 5% milk in TBST (TBS + 0.1% Tween-20) for at least 1 h at room temperature and incubated with primary antibodies diluted in 5% milk in TBST overnight at 4 °C. Membranes were then washed three times with TBST, incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature, washed again and protein bands were detected using the SuperSignal West Pico enhanced chemiluminescence reagent (Thermo Fisher).
To assess the efficiency of TOP1 depletion, WCEs were obtained by lysis and sonication of cells in UTB buffer (8 M urea, 50 mM Tris-HCl, pH 7.5, 150 mM β-mercaptoethanol, protease inhibitor cocktail (Roche)). WCEs for RNase H activity assays and for determining protein levels of the RNase H2 subunits were prepared by lysing cells in 50 mM Tris-HCl pH 8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol (v/v), 1 mM DTT and 1 mM PMSF for 10 min on ice, and subsequent addition of an equal volume of 20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 10% glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for an additional 10 min. WCEs were cleared by centrifugation (17,000g for 10 min at 4 °C) and protein concentration was determined using the Bradford assay (Protein Assay Kit, BioRad). Protein samples (35 μg total protein) were run on NuPAGE 4-12% Bis-Tris Protein Gels (Thermo Fisher Scientific) and transferred to nitrocellulose or PVDF membranes. Membranes were blocked in 5% milk in TBST and immunoblotting was performed as described above. Immunoprecipitation. Cells were collected by trypsinization, washed once with PBS supplemented with 1 μM ADP-HPD (PARG inhibitor; Enzo) and 4 × 10 6 cells were snap-frozen in liquid nitrogen and then lysed in 1 ml of lysis buffer (50 mM HEPES pH 8.0, 100 mM KCl, 2 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM DTT, complete protease inhibitor cocktail (Roche), 1 μM ADP-HPD). Lysates were incubated with gentle rotation at 4 °C for 15 min and then centrifuged at 15,000g for 10 min. Fifty microlitres of total cell lysates were used as input and 950 μl were incubated with 5 μl of mouse anti-PARP1 antibody (Enzo (F1-23) ALX-804-211-R050) for 5 h at 4 °C. Protein G-agarose beads (60-μl slurry; Pierce) were added for an additional hour. Beads were collected by centrifugation, washed four times with lysis buffer and eluted by boiling in 60 μl 2× sample buffer. Samples were run on an 8% SDS-PAGE gel and immunoblotting was performed as described above (see 'Immunoblotting' section).
To analyse PARP1 poly(ADP-ribosylation) in a specific phase of the cell cycle, wild-type and RNASEH2A KO HeLa FUCCI cells were trypsinized, washed once with PBS, collected in tubes with PBS supplemented with 3% FCS and 1 μM ADP-HPD, and sorted on the basis of mKO2-Cdt1 (G1 phase) and mAG-Geminin (S/G2/M phases) fluorescence on a BD Biosciences FACS Aria II instrument. 4 × 10 6 FACS-sorted cells were snap-frozen and lysed as described above. Equivalent amounts of proteins (~0.5-1 mg) were incubated with 25 μl of PARP1-Trap_A pre-equilibrated bead slurry (ChromoTek) for 2.5 h at 4 °C, washed four times with lysis buffer and eluted by boiling in 2× sample loading buffer (31.25 mM Tris pH 6.8, 25% glycerol, 1% SDS, 0.01% bromophenol blue, β-mercaptoethanol) before immunoblotting. Samples were run on a NuPAGE 4-12% Bis-Tris Protein Gel (Thermo Fisher Scientific) and immunoblotting was performed as described above. Antibodies. The following antibodies were used for immunofluorescence and immunoblotting at the indicated dilutions: sheep anti-pan-RNase H2 (raised against human recombinant RNase H2 13 , immunoblots 1:1,000, immunoprecipitation 5 μl per 1 ml lysate); rabbit anti-RNASEH2C (Proteintech 16518-1-AP; immunoblots 1:1,000); rabbit anti-RNASEH2A (Origene TA306706, immunoblots 1:1,000); mouse anti-RNASEH2A (Abcam ab92876; immunofluorescence 1:500); mouse anti-RNASEH2A G-10 (Santa Cruz Biotechnologies sc-515475; western blot 1:1,000); mouse anti-γH2AX JBW301 (Millipore 05-636, immunofluorescence 1:800-1:2,000); rabbit anti-RAD51 H-92 (Santa Cruz Biotechnologies sc-8349, immunofluorescence 1:150); rabbit anti-BRCA1 45 (immunoblots 1:1,000); mouse anti-Cas9 (Diagenode C15200203, immunoblots 1:1,000); rabbit anti-PARP1 H-250 (Santa Cruz Biotechnologies sc-7150, immunoblots 1:1,000); mouse anti-PAR 10H (Enzo ALX-804-220-R100, immunoblots 1:1,000); rabbit anti-Topoisomerase I (Abcam ab109374; immunoblots 1:5,000); rabbit anti-DYKD-DDDK (Cell Signaling Technologies 2368, immunoblots 1:1,000); rabbit anti-actin (Sigma A2066, immunoblots 1:5,000); mouse anti-α-tubulin DM1A (Millipore CP06, immunoblots 1:5,000); mouse anti-α-tubulin B512 (Sigma T6074, immunoblots 1:5,000); rabbit anti-GAPDH (Sigma G9545, immunoblots 1:20,000); mouse anti-vinculin (Sigma V9264, immunoblots 1:1,000); rabbit anti-DNA polymerase beta (Abcam ab26343, immunoblots 1:1,000); rabbit anti-cleaved caspase-3 (Cell Signaling Technologies 9661S, immunofluorescence 1:800). Cell Titer Glo assay. Two hundred cells per condition were plated on 96-well assay plates in technical triplicates either in drug-free medium or in a range of MMS concentrations. MMS was washed out 24 h later and cells were grown in drug-free medium for another 48 h. Cell viability was analysed using the Cell Titer Glo assay kit (Promega) according to the manufacturer's instructions. Luminescence was read on an Envision 2104 plate reader (Perkin Elmer). Detection of ribonucleotides in genomic DNA. Total nucleic acids were isolated from 10 6 cells by lysis in ice-cold buffer (20 mM Tris-HCl pH 7.5, 75 mM NaCl, 50 mM EDTA) and subsequent incubation with 200 μg ml −1 proteinase K (Roche) for 10 min on ice followed by addition of sarkosyl (Sigma) to a final concentration of 1%. Nucleic acids were sequentially extracted with TE-equilibrated phenol, phenol:chloroform:isoamyl alcohol (25:24:1), and chloroform, and then precipitated with isopropanol. Nucleic acids were collected by centrifugation, washed with 75% ethanol, air-dried and dissolved in nuclease-free water.
For alkaline gel electrophoresis, 500 ng of total nucleic acids were incubated with 1 pmol of purified recombinant human RNase H2 32 and 0.25 μg of DNase-free RNase (Roche) for 30 min at 37 °C in 100 μl reaction buffer (60 mM KCl, 50 mM Tris-HCl pH 8.0, 10 mM MgCl 2 , 0.01% BSA, 0.01% Triton X-100). Nucleic acids Letter reSeArCH were ethanol-precipitated, dissolved in nuclease-free water and separated on a 0.7% agarose gel in 50 mM NaOH, 1 mM EDTA. After electrophoresis, the gel was neutralized in 0.7 M Tris-HCl pH 8.0, 1.5 M NaCl and stained with SYBR Gold (Invitrogen). Imaging was performed on a FLA-5100 imaging system (Fujifilm), and densitometry plots generated using an AIDA Image Analyzer (Raytest). RNase H2 activity assay. Recombinant RNase H2 was expressed in Rosetta-2 Escherichia coli cells using a polycistronic construct based on pGEX6P1 (pMAR22) and purified as previously described 32 . Site-directed mutagenesis to introduce the D34A and D169A or P40D and Y210A mutations was performed using the Quikchange method (Agilent). To measure enzyme activity, a range of RNase H2 concentrations (0.06-2 nM) was incubated with 2 μM substrate in 5-μl reactions (in a buffer containing 60 mM KCl, 50 mM Tris-HCl pH 8.0, 10 mM MgCl 2 , 0.01% BSA and 0.01% Triton X-100) at 37 °C for 30 min or 1 h. Substrate was formed by annealing a 3′-fluorescein-labelled oligonucleotide (GATCTGAGCCTGGGaGCT, DRD-DNA; or gaucugagccugggagcu, RNA-DNA; uppercase DNA, lowercase RNA) to a complementary 5′-dabcyl-labelled DNA oligonucleotide (Eurogentec). Reactions were stopped by adding an equal volume of 96% formamide, 20 mM EDTA, and heating at 95 °C. Products were resolved by denaturing PAGE (20%, 1× TBE), visualized on a FLA-5100 imaging system (Fujifilm) and quantified using ImageQuant TL (GE Healthcare).
To assess RNase H2 activity in WCEs a FRET-based fluorescent substrate release assay was performed as previously described 32 . RNase H2 specific activity was determined against a DRD-DNA substrate (described above). Activity against a double-stranded DNA substrate of the same sequence was measured and used to correct for non-RNase H2 activity against the DRD-DNA substrate. Reactions were performed in 100 μl of buffer with 250 nM substrate in 96-well flat-bottomed plates at 25 °C. Whole cell lysates were prepared as described above, and the final protein concentration used per reaction was 100 ng μl −1 . Fluorescence was read for 100 ms using a VICTOR2 1420 multilabel counter (Perkin Elmer), with a 480-nm excitation filter and a 535-nm emission filter. Ex vivo CLL studies. Peripheral blood mononuclear cells were isolated from blood samples collected from patients with a new or existing diagnosis of CLL, irrespective of the stage of disease or duration or type of treatment from two Birmingham hospitals (Heartlands and Queen Elizabeth). This study was approved by the South Birmingham Ethics Committee (REC number 10/H1206/58), performed according to institutional guidelines and written consent was obtained from all participants.
Primary CLL cells (5 × 10 4 ) and CD40L-expressing mouse embryonic fibroblasts (5 × 10 3 ) were seeded in each well of a 96-well plate (Corning) in 100 μl of RPMI medium supplemented with 10% FBS (Sigma-Aldrich, UK) and 25 ng ml −1 IL-21 (eBioscience) 46 . After 24 h, 200 μl more medium was gently added and cells were incubated for another 48 h. The medium was then aspirated, replaced with 200 μl of medium containing talazoparib and cells were incubated for a further 72 h. The cytotoxic effect of PARPi was determined by propidium iodide exclusion as measured by flow cytometry with an Accuri C6 flow cytometer (Applied Biosystems). Only cells which entered the cell cycle upon stimulation (as determined by forward-and side-scatter FACS profiles), were considered for analysis. Data was expressed as a surviving fraction relative to untreated cells. For gating strategies, see Supplementary Fig. 2 . MLPA assay. Genomic DNA was isolated from primary CLL cells using the Flexigene kit (Qiagen). To identify deletions in RNASEH2B gene the MLPA assay was performed on approximately 100 ng of genomic DNA (gDNA) per sample using the P388-A2 SALSA MLPA kit (MRC-Holland) according to the manufacturer's protocol. Two microlitres of amplified products were separated by capillary electrophoresis on an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems) with a GeneScan 600 LIZ Size Standard (Thermo Fisher). Data were analysed using GeneMaker software v.2.4.0 (SoftGenetics). Data were normalized using gDNA from four control reference samples. Copy number changes represented as a MLPA ratio were detected by comparing normalized peak intensities between the reference and the CLL samples. The MLPA ratio thresholds (X) were set as follows: 0.75 ≥ X ≤ 1.25, diploid sample; 0.4 ≥ X < 0.75, monoallelic deletion; X < 0.4, biallelic deletion. Samples showing either a s.d. of control probes above 0.15, or samples with large Q fragment peaks and with more than four control probes having MLPA ratios out of diploid range were excluded from the analysis. CGH array. Genotyping of CLL samples was accomplished using HumanCoreExome BeadChip arrays (Illumina) by UCL Genomics in accordance with the Infinium HTS Assay protocol (15045736_A, Illumina). Genotypes were called by GenomeStudio software Genotyping Module v.3.1 (Illumina). A call rate of 98% was accepted as the primary quality control for each sample. Log R Ratio and B Allele Frequency values generated by the GenomeStudio software were used to assess allelic losses in chromosome 13q. Analysis of CNAs in the RB1-RNASEH2B region in CRPC. CRPC (n = 226) whole exome sequencing data generated by the International Stand Up To Cancer/ Prostate Cancer Foundation Prostate Cancer Dream Team were downloaded and re-analysed 28, 47 . Paired-end sequencing reads were aligned to the human reference genome (GRCh37/hg19) using BWA (v.0.5.9), with default settings and re-aligned using stampy (v.1.0.2). ASCAT (v.2.3) was used to estimate CNA, tumour purity and ploidy. Xenograft experiments. Female athymic CD-1 nude mice (5-7-weeks old, Charles River Laboratories) were used for in vivo xenograft studies and quarantined for at least 1 week before experiments. Exponentially growing wild-type RNASEH2A or RNASEH2A KO HCT116 TP53 KO cells were injected subcutaneously into the bilateral flanks of each animal (2 × 10 6 cells per flank). Tumours were measured by caliper every 3-4 days and tumour volume was determined by the formula (length × width 2 )/2. When the tumour volumes reached approximately 100 mm 3 (10 days after injection), mice were randomized into treatment and control groups (8 animals per group, 32 animals in total; sample size was determined based on previous relevant studies). Talazoparib (BMN673, 0.333 mg kg −1 , pharmacological grade, a gift from T. Heffernan and N. Feng) or vehicle (10% N,Ndimethylacetamide (ACROS Organics), 5% Solutol HS 15 (Sigma-Aldrich) in PBS (Gibco)) was administered once daily by oral gavage (0.1 ml per 10 g of body weight) for the indicated length of time, or until the tumour reached the maximum size (15 mm in any direction) or ulcerated, or a body conditioning score of two was reached, as determined by UK Home Office regulations. The data reported are the average tumour volumes per mouse. Individual flanks that showed no evidence of tumour growth before initiation of treatment were excluded from subsequent measurements and analysis.
A subsequent experiment was performed by injecting exponentially growing HCT116 TP53 KO RNASEH2A KO cells complemented either with an empty vector or a vector encoding wild-type RNASEH2A (2 × 10 6 cells per flank). To increase the potential treatment window, mice were randomized into treatment and control groups (8 animals per group, 32 animals in total), and treatment started 3 days after injection when palpable tumours were formed. The treatment was administered as described above. Animals that showed no evidence of tumour growth on both flanks within the first 11 days of treatment were excluded from analysis.
The technician performing tumour measurements was blinded to the experimental design and identity of cells injected. All animal studies were carried out under Project Licence PPL 70/8897 approved by the UK Home Office and by the University of Edinburgh Animal Welfare and Ethical Review Body. Statistical analysis. Data were analysed using a two-tailed Student's t-test and a two-way ANOVA under the assumption of normal distribution for biological parameters. No corrections for multiple testing were made. Tests used are indicated in respective figure legends. The number of samples (n) in figure legends represents independent biological replicates, unless stated otherwise. No statistical methods were used to determine the sample size before starting experiments. Cell biology experiments were not randomized and the investigators were not blinded with regards to sample allocation and evaluation of the experimental outcome. For xenograft experiments blinding and randomization were performed. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. Results of PARP inhibitor CRISPR screens, source data for mouse xenograft experiments, unprocessed images of immunoblots and examples of gating strategies for FACS experiments are provided as Supplementary Information. All other datasets generated during this study are available from the corresponding authors upon reasonable request.
Extended Data Fig. 3 | Functional homologous recombination, increased replication-associated DNA damage and synthetic lethality with the loss of BRCA1 or BRCA2 in RNase H2-deficient cells. This figure is related to Fig. 2. a-d , Homologous recombination is not affected by the inactivation of RNase H2. a, Micrographs of wild-type and RNASEH2A KO RPE1-hTERT Cas9 TP53 KO and cells exposed to 3 Gy of X-rays (IR) and assessed using γ-H2AX and RAD51 immunofluorescence 4 h later. Images are representative of three biologically independent experiments. b. Quantification of the experiment in a at the indicated time points after irradiation, plotted as a percentage of cells with more than five γ-H2AX and RAD51 colocalizing foci. Fig. 3a-c . a, Schematic representation of CRISPR screens for suppressors of talazoparib sensitivity in RNase H2-deficient cells. Cas9-expressing cells were transduced with the TKOv1 library, talazoparib was added on day 6 (t6; HeLa, 20 nM; RPE1-hTERT, 50 nM) and cells were cultured in its presence until day 18 (t18). Cells were subcultured once at day 12 (RPE1) or 13 (HeLa). sgRNA representations in the initial (t6) and final (t18) populations were quantified by next-generation sequencing. Gene knockouts that were enriched at day 18 over day 6 were identified by MAGeCK 42 . b, CRISPR-mediated inactivation of RNASEH2A and/ or PARP1 in cell lines used in c-e and Fig. 3b . WCEs were processed for immunoblotting with the indicated antibodies. KAP1 was used as a loading control. Immunoblots are representative of two biologically independent experiments. c-e, Loss of PARP1 restores PARPi-resistance in RNASEH2A KO Fig. 4 . a, b, Proliferating cells, and not quiescent cells, are the major population of viable cells in ex vivo cultured primary CLL patient samples irrespective of treatment group. Quantification of absolute (a) and relative (b) quiescent and proliferating cell numbers as determined by FACS analysis of the primary CLL samples used in Fig. 4b, c . Wild-type RNASEH2B, n = 8 individual samples; monoallelic deletion, n = 4 individual samples; biallelic deletion, n = 9 individual samples. Data are mean ± s.d. from three technical replicates. FACS gating strategy for stimulated peripheral blood lymphocytes (PBLs) from CLL patients is shown in Supplementary  Fig. 2 . c, RNase H2-deficient primary CLL cells have reduced survival when cultured with olaparib. Data are the mean of individual samples ± s.e.m. (n = 3 biologically independent CLL samples per group, each analysed in technical triplicates). P value from a two-way ANOVA. d, Talazoparib selectively inhibits the growth of RNASEH2A KO xenograft tumours. RNASEH2A KO cells complemented either with empty vector or wild-type RNASEH2A were injected subcutaneously into bilateral flanks of CD-1 nude mice. Mice were randomized to either vehicle or talazoparib (0.333 mg kg −1 ) treatment groups (eight animals per group) and tumour volumes were measured twice weekly. Data are mean ± s.e.m. P values are from two-way ANOVA under the null hypothesis that talazoparib does not suppress the tumour growth.
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
Flow cytometry data were collected using CellQuest Pro v6.0, FACSDIVA v8.0.1, v6.1.3 and BD Accuri C6.
Data analysis
